Related Experiment Video
Updated: Jun 13, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Myxoma virus: propagation, purification, quantification, and storage
Sherin E Smallwood1, Masmudur M Rahman, Dorothy W Smith
1College of Medicine, University of Florida, Gainesville, Florida, USA.
Abstract:
Myxoma virus (MYXV) is a member of the Poxviridae family and prototype for the genus Leporipoxvirus. It is pathogenic only for European rabbits, in which it causes the lethal disease myxomatosis, and two North American species, in which it causes a less severe disease. MYXV replicates exclusively in the cytoplasm of the host cell. Although not infectious in humans, its genome encodes proteins that can interfere with or modulate host defense mechanisms; it is able to productively infect a number of human cancer cell lines, but not normal human cells, and has also been shown to increase survival time in mouse models of human glioma. These characteristics suggest that MYXV could be a viable therapeutic agent, e.g., in anti-inflammatory or anti-immune therapy, or as an oncolytic agent. MYXV is also an excellent model for poxvirus biology, pathogenesis, and host tropism studies. It is easily propagated in a number of cell lines, including adherent cells and suspension cultures, and minimal purification is required to provide a stock for in vivo and in vitro studies.
Insights
Myxoma virus (MYXV), a poxvirus, infects rabbits but not humans. It shows potential as an oncolytic agent and for anti-inflammatory therapies due to its cancer cell targeting and immune modulation capabilities.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Myxoma virus (MYXV) belongs to the Poxviridae family and genus Leporipoxvirus.
- MYXV is pathogenic in European rabbits, causing lethal myxomatosis, and less severe disease in two North American rabbit species.
- The virus replicates exclusively in the host cell cytoplasm.
Purpose of the Study:
- To explore the therapeutic potential of Myxoma virus (MYXV) as an oncolytic agent and for anti-inflammatory/anti-immune therapies.
- To highlight MYXV's utility as a model for studying poxvirus biology, pathogenesis, and host tropism.
- To investigate MYXV's ability to infect human cancer cell lines while sparing normal human cells.
Main Methods:
- Literature review and analysis of MYXV's biological characteristics and interactions with host cells.
- Examination of MYXV's genomic properties, including proteins that modulate host defense mechanisms.
- Assessment of MYXV's infectivity in various human cancer cell lines versus normal human cells.
- Review of studies on MYXV in mouse models of human glioma.
Main Results:
- MYXV infects human cancer cell lines but not normal human cells.
- MYXV has demonstrated increased survival times in mouse models of human glioma.
- The virus's genome encodes proteins that can interfere with or modulate host defense mechanisms.
- MYXV is easily propagated in cell cultures with minimal purification.
Conclusions:
- MYXV exhibits potential as a therapeutic agent, particularly as an oncolytic virus and for anti-inflammatory or anti-immune applications.
- Its selective infectivity for cancer cells and ability to modulate host defenses support its therapeutic promise.
- MYXV serves as a valuable model for understanding poxvirus biology and host interactions.
